Individual and cumulative effect of prostate cancer risk‐associated variants on clinicopathologic variables in 5,895 prostate cancer patients
The Prostate2009Vol. 69(11), pp. 1195–1205
Citations Over TimeTop 1% of 2009 papers
A. Karim Kader, Jielin Sun, Sarah D. Isaacs, Kathleen E. Wiley, Guifang Yan, Seong‐Tae Kim, Helen Fedor, Angelo M. De Marzo, Jonathan I. Epstein, Patrick C. Walsh, Alan W. Partin, Bruce J. Trock, Su-Su Zheng, Jianfeng Xu, William B. Isaacs
Abstract
The vast majority of PCa risk-associated SNPs are not associated with aggressiveness and clinicopathologic variables of PCa. Correspondingly, they have minimal utility in predicting the risk for developing more or less aggressive forms of PCa.
Related Papers
- → DEFINING PROSTATE SPECIFIC ANTIGEN PROGRESSION AFTER RADICAL PROSTATECTOMY: WHAT IS THE MOST APPROPRIATE CUT POINT?(2001)408 cited
- → Biochemical relapse following radical prostatectomy and miR‐200a levels in prostate cancer(2011)55 cited
- → Multiple prostate cancer cores with different Gleason grades submitted in the same specimen container without specific site designation: should each core be assigned an individual Gleason score?(2009)38 cited
- → Understanding differences between high and low volume hospitals for radical prostatectomy(2007)15 cited
- [Single nucleotide polymorphisms and prostate cancer].(2014)